« DRUG DELIVERY
example where doxorubicin was delivered into various tumor cells via folate receptor and demonstrated increased cytotoxicity [35].
Challenges in Developing Targeted Drug Delivery Systems
1. They have not been extensively characterized in a clinical setting i.e., pharmacokinetics, biodistribution, and toxicity.
2. Each system is unique and must be evaluated as a new formulation. Development of suitable screening methodologies for determining optimal characteristics of nanocarriers is still not clear. Therefore, successful targeting strategies must be determined experimentally on a case-by-case basis, which is laborious.
3. Major developmental concerns have to be resolved such as formulation stability, particle size uniformity, control of drug release rate and large scale manufacture of sterile preparations before these formulations can become therapeutically relevant.
4. The overall cost is very high and furthermore, the development process is time consuming due to its unique requirements.
5. The relevance of in vitro tests of activity, selectivity, uptake, and toxicity of targeted systems to the animal or human is still an area of research and great amount of work is needed before clinical application of such systems.
Author Biographies
Dev Prasad is a Ph.D. Candidate in Pharmaceutics at Massachusetts College of Pharmacy and Health Sciences, Boston MA. He received his M.S. (Pharmaceutics) from Massachusetts College of Pharmacy and Health Sciences, Boston MA in 2010. His active research is focused on the solid state
characterization and formulation of poorly water soluble drug using approaches such as Solid dispersions, and SEDDS.
Dr. Harsh Chauhan is an Assistant Professor at Creighton University, Omaha, NE. Dr. Chauhan received his Ph.D. in Pharmaceutics from MCPHS, Boston, MA. His research emphasizes on amorphous systems and solid lipid nanoparticles. He worked as visiting scientist at Vertex pharmaceuticals and his professional affiliations include AAPS, ACS and AACP.
Enhanced Bioavailability Through High Purity Lipid Vehicles
Super Refined Oils ®
SUPER REFINED OILS are naturally derived oils purified using Croda’s proprietary chromatography process, which removes polar and oxidative impurities. Super Refining improves the oxidative stability of the triglyceride without altering the natural fatty acid composition. This reduces the potential for adverse interactions between the excipient and the active ingredient, enhancing the stability and performance of the active.
n Dramatically reduces impurity profile n Improves oxidative stability n Enhances API stability n Universally accepted excipients
Available products include: Super Refined® Super Refined® Super Refined® Super Refined® Super Refined® Super Refined® Super Refined® Super Refined®
North America email:
hc-usa@croda.com
Europe, Middle East & Africa email:
hc-europe@croda.com
Latin America email:
marketinglatam@croda.com Asia Pacific
email:
hc-asia@croda.com www.croda.com/healthcare
Castor Oil Corn
Cottonseed Olive
Peanut
Safflower Sesame Soybean
www.americanpharmaceuticalreview.com | EnhancedBioavailbilityAPR-.5pislandw_noQR*
_13.indd 1
| 69 8/13/13 12:06 PM
»
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148 |
Page 149 |
Page 150 |
Page 151 |
Page 152 |
Page 153 |
Page 154 |
Page 155 |
Page 156